Related Experiment Video
Updated: May 22, 2026

Anatomical Reconstructions of the Human Cardiac Venous System using Contrast-computed Tomography of Perfusion-fixed Specimens
Published on: April 18, 2013
Trimetazidine in the prevention of contrast induced nephropathy after coronary angiogram
M M Rahman1, S S Haque, B Rokeya
1Department of Cardiology, Bangabandhu Sheikh Mujib Medical University (BSMMU), Dhaka, Bangladesh.
Insights
Trimetazidine effectively prevents contrast-induced nephropathy (CIN) in patients undergoing coronary angiography. This study found a significant reduction in CIN incidence when trimetazidine was administered with saline compared to saline alone.
Area of Science:
- Cardiology
- Nephrology
- Pharmacology
Background:
- Contrast-induced nephropathy (CIN) is a significant complication following coronary angiography.
- CIN increases mortality, morbidity, and necessitates interventions like hemodialysis.
- Patients with elevated serum creatinine are at higher risk for CIN.
Purpose of the Study:
- To evaluate the efficacy of trimetazidine (TMZ) in preventing CIN.
- To compare the incidence of CIN in patients receiving trimetazidine plus hydration versus hydration alone.
Main Methods:
- A prospective randomized controlled trial involving 400 patients undergoing coronary angiography.
- Patients were divided into two groups: trimetazidine plus saline hydration (n=200) and saline hydration alone (control, n=200).
- Incidence of CIN was assessed in both groups.
Main Results:
- The incidence of CIN was significantly lower in the trimetazidine group (4%) compared to the control group (14%) (p<0.05).
- Trimetazidine administration with saline demonstrated a protective effect against CIN.
- The findings suggest a beneficial role for trimetazidine in this patient population.
Conclusions:
- Trimetazidine is effective in preventing contrast-induced nephropathy in patients undergoing coronary angiography.
- The study supports the use of trimetazidine as an adjunct therapy to hydration for CIN prevention.
- Further research may explore the long-term benefits and optimal dosing of trimetazidine for CIN prophylaxis.
Abstract:
This prospective randomized, controlled trial was done to evaluate the efficacy of trimetazidine in the prevention of contrast induced nephropathy in patients with raised serum creatinine levels undergoing coronary angiogram. This study was performed in the Department of Cardiology, Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh from April 2009 to March 2010. Contrast-induced nephropathy (CIN) is a serious complication of coronary angiography that is associated with considerably increased mortality and morbidity, including the need for short-term haemodialysis, extended hospitalisation and permanent impairment of renal function. Trimetazidine (TMZ) has been described as a cellular anti-ischaemic agent. This study was trial with 400 patients. Among them 200 patients treated with trimetazidine plus hydration with normal saline and 200 patients (control) given hydration by normal saline only. It was found that the incidence of CIN was significantly (p<0.05) reduced by trimetazidine administration with saline in comparison with saline alone in patients undergoing coronary angiogram (4% vs. 14%).
Related Concept Videos
Imaging Studies VII: Vascular Imaging
Imaging Studies for Cardiovascular System V: CT
Imaging Studies III: Computed Tomography
Acute Kidney Injury IV: Diagnostic Studies and Prevention
Cardiac Catheterization I: Pre-Procedure Overview
Cardiac Catheterization IV: Nursing Management
